Alternatives such as anti-IL-5 or anti-IgE therapies may be appropriate for these patients, particularly when continued control of CRSwNP is necessary after dupilumab discontinuation [4]. This evidence concerns the gene IL5 and chronic rhinosinusitis with nasal polyps.